Stable

Hologic and Siemens Section 337 Mammography Dispute

Reis Renneker

Written by Reis Renneker

Competing Hologic and Siemens ITC complaints could affect mammography imports. Importers should assess exposure before any exclusion order.

Hologic and Siemens Section 337 Mammography Dispute

Competing Section 337 mammography systems complaints have placed Hologic and Siemens at the center of a potentially significant medical device import dispute. Although no investigation or exclusion order has been issued, hospitals, distributors, importers, and customs brokers should evaluate product exposure before the proceedings advance.

Two Competing Mammography System Complaints

Hologic's Complaint Against Siemens

Hologic, Inc. filed complaint DN 3951 on November 16, 2026, targeting certain mammography systems with focal spot compensation technology and related components, including x-ray tubes. The named respondents are Siemens Healthineers AG, Siemens Healthcare GmbH, and Siemens Medical Solutions USA, Inc.

Hologic alleges that the importation and sale of accused Siemens products infringe its intellectual property rights. The complaint seeks a limited exclusion order, cease-and-desist orders, and a bond covering certain import activity during the 60-day Presidential review period that would follow a final ITC remedy.

A limited exclusion order, if ultimately issued, would generally apply to infringing products associated with the named respondents. It would not automatically prohibit every mammography system or x-ray tube from entering the United States. Product scope, patent coverage, respondent relationships, and the language of any final order would determine the practical reach.

Siemens' Complaint Against Hologic

Siemens Medical Solutions USA, Inc. filed complaint DN 3952 on the same day against Hologic. Siemens alleges infringement involving Hologic's Envision Mammography Platform and technologies associated with 3D mammography and digital breast tomosynthesis systems.

Siemens seeks substantially similar remedies, including a limited exclusion order, cease-and-desist relief, and a bond during the Presidential review period. The competing filings create parallel import-risk scenarios for two major participants in the U.S. mammography market.

These are complaints, not findings of infringement. The ITC has not yet determined whether to institute either investigation. Until institution occurs, the proceedings remain at the preliminary complaint stage, and no exclusion order restricts entry of the identified products.

How the Section 337 Process Could Affect Imports

Institution Comes Before Any Import Restriction

The ITC generally reviews a complaint for procedural and substantive sufficiency before deciding whether to institute an investigation. If an investigation is instituted, the Commission typically defines its scope, identifies the respondents, and assigns the matter for adjudication. Patent validity, infringement, domestic industry, importation, and potential defenses may then be contested.

An instituted investigation still does not mean that the accused merchandise is inadmissible. Importers may generally continue entering products unless another legal restriction applies or the ITC later issues temporary or final relief. The time between institution and a final determination can nevertheless create substantial commercial uncertainty, particularly for products with long procurement cycles and specialized installation requirements.

Exclusion Orders Are Not Additional Tariffs

A Section 337 exclusion order addresses admissibility rather than duty rates. It can direct U.S. Customs and Border Protection to exclude covered articles from entry. Paying additional customs duties would not cure a product that falls within the scope of an enforceable exclusion order.

Cease-and-desist orders operate differently. They generally govern certain domestic commercial conduct, potentially including the sale or distribution of covered inventory already located in the United States. Their application depends on the parties, products, and conduct specified by the Commission.

If relief is issued, a 60-day Presidential review period generally follows. The ITC may establish a bond under which covered goods can be entered during that period. A bond is not the same as ordinary customs duty, and its amount and conditions would be set in connection with the case.

Importers should therefore keep tariff classification, duty liability, patent scope, and exclusion-order exposure in separate analytical tracks. Each presents a different compliance question and requires different documentation.

Public Interest and Medical Supply Considerations

The Commission's Public Interest Factors

The ITC has invited public interest comments addressing how the requested remedies could affect public health and welfare, competitive conditions in the United States, domestic production of like or directly competitive articles, and U.S. consumers. These factors are particularly relevant when the accused products support breast cancer screening, diagnostic imaging, and continuity of hospital services.

Public interest submissions are due by close of business eight calendar days after Federal Register publication. The complainants may submit replies within three calendar days after that deadline. Each submission is limited to five pages, making focused factual analysis essential.

Hospitals, imaging centers, distributors, and other stakeholders should verify the official filing deadline and submission requirements before acting. The short calendar-based period leaves little room for internal approvals, legal review, or collection of operational evidence.

Evidence That Can Inform Public Interest Comments

Effective comments generally do more than express support for continued product availability. Stakeholders should consider quantifying operational consequences, such as the number of installed systems, patient volumes, geographic service coverage, replacement lead times, technician availability, and compatibility with existing clinical workflows.

Other relevant considerations may include whether alternative systems are reasonably available, how quickly facilities could validate replacements, and whether switching platforms would require retraining, construction, software integration, or new regulatory approvals. Distributors may also be positioned to explain inventory levels, spare-parts constraints, and service obligations.

Public interest arguments do not necessarily resolve the underlying patent issues. They can, however, help the Commission evaluate whether a requested remedy should be tailored, delayed, or otherwise structured to account for health, competition, production, and consumer effects.

Importer and Broker Response Priorities

Build a Product-Level Exposure Map

Importers should begin by identifying which mammography systems, components, and x-ray tubes could potentially fall within the complaints. Reviews should connect commercial model numbers with manufacturer part numbers, product descriptions, technical specifications, country of origin, supplier identity, and importer of record data.

Broad descriptions such as “medical equipment” or “x-ray components” are not sufficient for managing a product-specific intellectual property dispute. Importers need traceability from purchase order through entry line, including invoices, packing lists, technical literature, serial numbers, and internal product master records.

The review should also distinguish complete systems from replacement parts, service components, demonstration units, temporary imports, and returned merchandise. A future exclusion order may define covered articles differently from commercial catalog groupings.

Coordinate Legal and Customs Functions

Patent counsel, trade compliance teams, procurement leaders, and customs brokers should establish clear responsibilities before an investigation reaches an advanced stage. Patent counsel can assess infringement allegations and potential design-around positions. Trade teams can identify import flows, ports, entry data, and recordkeeping gaps. Procurement teams can evaluate supplier commitments and alternatives.

Customs brokers should not be expected to determine patent infringement from abbreviated entry descriptions. Importers should provide brokers with actionable written instructions, including affected part numbers, escalation procedures, and any approved treatment for potentially covered goods.

If an exclusion order is eventually issued, importers may need to demonstrate that particular products fall outside its scope. Detailed technical documentation, manufacturer certifications, engineering comparisons, or administrative guidance may become important. Unsupported declarations and generic invoice language may not satisfy border authorities.

Importers should also review contracts for intellectual property indemnification, delivery obligations, inventory ownership, and allocation of costs arising from detention, exclusion, exportation, or reconfiguration. Early planning can reduce the risk that a legal dispute becomes an uncontrolled supply chain disruption.

Recent Developments
  • On November 16, 2026, Hologic, Inc. filed ITC Section 337 complaint DN 3951* (Certain Mammography Systems with Focal Spot Compensation Technology and Components Thereof, Including X-Ray Tubes) against Siemens Healthineers AG (Germany), Siemens Healthcare GmbH (Germany), and Siemens Medical Solutions USA, Inc. (Malvern, PA). Hologic alleges infringement via importation and sale of accused systems and seeks a limited exclusion order, cease-and-desist orders, and a bond during the 60-day Presidential review period.
  • Siemens Medical Solutions USA, Inc. filed competing ITC complaint DN 3952* the same day (Certain Mammography Systems and Components Thereof) against Hologic, Inc. (Marlborough, MA), alleging infringement by Hologic's Envision Mammography Platform of Siemens patents related to 3D mammography and digital breast tomosynthesis systems. Siemens seeks similar relief (limited exclusion order, cease-and-desist orders, and a bond).
  • The ITC issued notices of receipt on November 17, 2026, and solicited public interest comments* on both complaints (FR Docs. 2026-23619 and 2026-23627). Comments on impacts to public health/welfare, competitive conditions, U.S. production of like articles, and consumers were due eight calendar days after Federal Register publication (around November 20, 2026). The Commission has not yet decided whether to institute investigations.
  • Parallel U.S. District Court patent suits were filed in Delaware around the same time*, with Siemens Medical Solutions USA suing Hologic on November 13, 2026 (asserting U.S. Patent No. 8,284,894, recently acquired from Philips) and Hologic suing Siemens entities on November 16, 2026 (asserting five patents from 2013-2018 on focal-spot compensation technology). This expands the companies' ongoing mammography IP dispute.
  • No recent X (Twitter) practitioner discussions matching the topic were identified in searches. Industry coverage appeared in outlets such as AuntMinnie, Radiology Business, and ip fray on November 17-18, 2026.
1 2 3

Frequently Asked Questions

Is There Currently an Exclusion Order on Hologic or Siemens Mammography Systems?

No. The two matters are complaints, and the ITC has not yet decided whether to institute investigations. Filing a complaint does not itself prohibit importation. Any enforceable exclusion order would require further proceedings and Commission action.

Would an Exclusion Order Increase the Duty Rate?

No. An exclusion order generally affects whether covered articles may enter the United States. It does not function as an additional tariff. A product within the scope of an enforceable order can potentially be denied entry regardless of whether all ordinary customs duties have been paid.

What Is the Difference Between a Limited Exclusion Order and a Cease-and-Desist Order?

A limited exclusion order generally directs CBP to exclude covered articles associated with specified respondents. A cease-and-desist order generally restricts designated conduct within the United States, which may include selling or distributing covered inventory. The exact obligations depend on the final language of the order.

Should Hospitals and Imaging Centers Submit Public Interest Comments?

Facilities that depend on potentially affected systems should consider whether they possess concrete information relevant to patient access, replacement timelines, system compatibility, service continuity, or alternative capacity. Because submissions are limited to five pages and subject to a short deadline, comments should be concise, evidence-based, and directly connected to the requested remedies.

What Should Importers Do Before the ITC Decides Whether to Institute?

Importers should identify affected products and suppliers, preserve entry and technical records, review contracts, and create an internal escalation process. They should also monitor both proceedings separately because the allegations, accused technologies, respondents, and potential product scope are not identical.

Can Customs Brokers Determine Whether a Product Infringes a Patent?

Customs brokers generally process entries based on information and instructions supplied by importers. Patent infringement and exclusion-order scope can require detailed legal and technical analysis. Importers should obtain appropriate counsel and provide brokers with specific product lists, documentation requirements, and escalation instructions.

How Stable Software Can Help

Supporting Broker-Led Importer Services

Section 337 risk reinforces the importance of accurate product records, disciplined customs processes, and clear communication between importers and their brokers. Although duty drawback software does not determine patent infringement or exclusion-order scope, brokers can strengthen client relationships by combining specialized trade expertise with efficient, technology-supported services.

Stable Software makes DrawbackAI, flat-license duty drawback software that U.S. customs brokers can white-label for importer clients and use to file under their own filer codes. Stable Software charges a flat software license and never takes a percentage of the refund. Customs brokerage firms evaluating technology-enabled client services can learn more about Stable Software's approach for customs brokers.

Resources

TypeResource
SourcePrimary source

✉️

Sign up for our newsletter

A monthly post on trade, tariffs, and customs, delivered straight to your inbox.